Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 12 of 16.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next»
    EudraCT Number: 2007-002671-14 Sponsor Protocol Number: CRAD001ADE14 Start Date*: 2008-02-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 15-month, multi-center, randomized, open-label, parallel group study investigating the renal tolerability, efficacy and safety of a CNI-free regimen (Certican® and MPA) versus a low-dose CNI- reg...
    Medical condition: heart transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10019314 Heart transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011473-33 Sponsor Protocol Number: CRAD001AFR10 Start Date*: 2009-06-22
    Sponsor Name:Novartis Pharma S.A.S.
    Full Title: Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés...
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004096-21 Sponsor Protocol Number: CRAD001O2101 Start Date*: 2008-12-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma
    Medical condition: advanced hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004934-14 Sponsor Protocol Number: EMASPK01 Start Date*: 2014-01-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY
    Medical condition: simultaneous pancreas/kidney allograft transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10048622 Pancreatic transplant LLT
    16.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016914-25 Sponsor Protocol Number: CEDRICStudie Start Date*: 2011-08-08
    Sponsor Name:Deutsches Herzzentrum Berlin
    Full Title: CEDRIC: Clopidogrel- Effects on Diameter Reduction and Intimal Hyperplasia in Long-term Follow up after Cardiac Transplantation
    Medical condition: Transplant vasculopathy after heart transplantation characterized by Stanford type B2 lesions in coronary angiography and by microvasculopathy proven in biopsy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004837-16 Sponsor Protocol Number: CRAD001C2454 Start Date*: 2006-10-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST
    Medical condition: gastrointestinal stromal tumors (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002070-21 Sponsor Protocol Number: CRAD001C2240 Start Date*: 2006-10-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met...
    Medical condition: Renal cell carcinomas arise from the proximal tubal epithelium. Alternatively known as clear-cell cancer or renal adenocarcinoma, RCC is characterized by a distinct clear or granular cell appearanc...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001563-36 Sponsor Protocol Number: CRAD001MIL04T Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)
    Medical condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-002102-22 Sponsor Protocol Number: CeCaRi Start Date*: 2007-10-10
    Sponsor Name:Gasthuisberg Leuven
    Full Title: Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant re...
    Medical condition: This study is designed to evaluate whether Certican® initiation, together with discontinuation of calcineurin inhibitors (CNIs) will have a beneficial effect on the renal function in maintenance he...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000690-36 Sponsor Protocol Number: TED14856 Start Date*: 2018-12-17
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) PT (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007021-32 Sponsor Protocol Number: CRAD001ADE13 Start Date*: 2007-05-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dos...
    Medical condition: de novo kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023439 Kidney transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000849-38 Sponsor Protocol Number: CRAD001C2223 Start Date*: 2005-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t...
    Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004346-40 Sponsor Protocol Number: CRAD001A2418 Start Date*: 2005-05-02
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Full title of the trial : Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy wit...
    Medical condition: de novo kidney transplantation (cadaveric, living unrelated or living related)
    Disease: Version SOC Term Classification Code Term Level
    M15 10023438 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015952-11 Sponsor Protocol Number: 0923 Start Date*: 2009-11-17
    Sponsor Name:Department of OncologyHerlev University Hospital
    Full Title: Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progressio...
    Medical condition: Patient with metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010029 Colorectal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018353-36 Sponsor Protocol Number: FARM8PRTEC Start Date*: 2010-05-01
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Myc...
    Medical condition: Paitents will be enrolled at least one year after heart transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006832-23 Sponsor Protocol Number: I06028 Start Date*: 2007-04-05
    Sponsor Name:CHU de Limoges
    Full Title: PIGREC Pharmacocinétique des Immunosuppresseurs chez les patients GREffés Cardiaques Étude multicentrique, ouverte, de mise au point de modèles pharmacocinétiques de population et d’estimateurs Ba...
    Medical condition: transplantation cardiaque
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007611 Cardiac transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006221-27 Sponsor Protocol Number: 146/2007/U/Sper Start Date*: 2008-04-01
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients
    Medical condition: HCV cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005422-76 Sponsor Protocol Number: CRAD001C24100 Start Date*: 2008-09-01
    Sponsor Name:PD Dr. Gerhard Treiber
    Full Title: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001
    Medical condition: Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014407-31 Sponsor Protocol Number: 09.07 Start Date*: 2009-10-06
    Sponsor Name:Odense Universitetshospital
    Full Title: Randomiseret fase II forsøg med irinotecan, cetuximab og everolimus (ICE) sammenlignet med capecitabin og oxaliplatin (CapOx) til patienter med gemcitabin resistent pancreascancer.
    Medical condition: Patienter med gemcitabin resistent pancreascancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012200-98 Sponsor Protocol Number: yCAN Start Date*: 2011-01-21
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun® Optoral and Certican® in comparison to standard immunosuppressive therapy in renal tra...
    Medical condition: Maintenance outpatient renal transplant recipients at least 6 months post-transplantation, no longer than 8 years after transplantation with a creeping serum creatinine (as calculated by CAN-Slope®...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 15:44:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA